5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Anti-viral Therapeutics Market has been Segmented by Drug Type (Herpes Anti-viral Drugs, Hepatitis Anti-viral Drugs, HIV Anti-viral Drugs, Influenza Anti-viral Drugs, and Other Anti-viral Drugs), Distribution Channel, and Geography.
Fastest Growing Market:
The anti-viral therapeutics market is expected to register a CAGR of 6.0%, over the forecast period. North America dominates the market, owing to the growing prevalence of hepatitis C and human immunodeficiency viruses (HIV) infections, coupled with the presence of a huge patient pool suffering from virally infectious diseases.
The market for anti-viral therapeutics has been considered according to the burden of the disease caused by viruses at the global level. The anti-viral therapeutics market is essentially split into anti-viral drug markets for herpes, hepatitis, HIV, and influenza, among other diseases. The market has also been segmented on the basis of distribution channels into hospital pharmacy, independent pharmacy, and online drug stores.
|By Drug Type|
|Herpes Anti-viral Drugs|
|Hepatitis Anti-viral Drugs|
|HIV Anti-viral Drugs|
|Influenza Anti-viral Drugs|
|Other Anti-viral Drugs|
|By Distribution Channel|
|Independent Pharmacy and Drug Store|
Report scope can be customized per your requirements. Click here.
HIV is a major global public health issue. According to the 2019 UNAIDS data, 24.5 million people were accessing antiretroviral therapy by the end of 2019. About 1.7 million people became newly infected with the virus in 2018. The vast majority of people living with HIV are located in low- and middle-income countries, with an estimated 66% living in Sub-Saharan Africa. However, the majority of HIV anti-viral consumption was exhibited in the North American region. Over the forecast period, the use of anti-virals in African countries is expected to increase multifold, as the majority of global companies are strategizing their HIV-based products in the emerging market.
To understand key trends, Download Sample Report
North America dominated the anti-viral therapeutics market, owing to the presence of well-established market players, as well as due to the growing prevalence of HIV and hepatitis C infections. The North American market is primarily driven by factors, such as the increasing occurrence of infectious diseases, increasing geriatric population base, and growing healthcare awareness, coupled with increasing healthcare expenditure in the region. However, there are limitations to market growth in the region, which include generic erosion and patent expiration of anti-viral drugs.
To understand geography trends, Download Sample Report.
The anti-viral therapeutics market is a fast-growing market. The current market share is majorly controlled by a few major pharmaceutical and biotechnology companies. There is a limited number of antiviral products in the market, and a large percentage of these drugs is expected to lose exclusivity in the coming future. This may be marked by the entry of generic manufacturers, expansion of market size, and lowering of market concentration.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
4.2.2 Advancements in Molecular Biology Promoting Drug Development
4.2.3 Growing Burden of HIV Infection
4.3 Market Restraints
4.3.1 High Cost of Antiviral Drug Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Herpes Anti-viral Drugs
5.1.2 Hepatitis Anti-viral Drugs
5.1.3 HIV Anti-viral Drugs
5.1.4 Influenza Anti-viral Drugs
5.1.5 Other Anti-viral Drugs
5.2 By Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Independent Pharmacy and Drug Store
5.2.3 Online Pharmacy
5.3 By Geography
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Bristol-Meyrs Squibb Company
6.1.3 Cipla Inc.
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Gilead Sciences Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Pfizer Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments